NCT01406132已完成1 期
A Phase 1, Open-Label, Mass Balance Study to Evaluate the Pharmacokinetics of ASP015K After a Single Oral Dose of 14C-Labeled ASP015K in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Pharmacokinetic assessment through radiographic and high performance liquid chromatography (HPLC) analysis of blood, urine and feces samples
研究概览
简要总结
The objective of this study is to evaluate pharmacokinetics, in particular the routes of excretion and extent of metabolism of ASP015K after a single oral dose of 14C-labeled ASP015K.
详细描述
Eligible subjects will be admitted to the clinical research unit and confined for a minimum of 8 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •The subject has a body weight of at least 45 kg and a body mass index (BMI) between 18 and 32 kg/m2, inclusive
- •The subject has been a non-smoker for at least 3 months prior to check-in
- •The subject agrees to sexual abstinence, is surgically sterile (with documentation provided by a healthcare professional), or is using a medically acceptable method to prevent pregnancy during the study period
- •The subject's clinical laboratory test results are within normal limits
- •The subject is medically healthy, with no clinically significant medical history or abnormalities
排除标准
- •The subject has a history of any clinically significant gastrointestinal, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy excluding non-melanoma skin cancer
- •The subject has a history of malabsorption syndrome or previous gastrointestinal surgery that could affect drug absorption or metabolism
- •The subject has a recent history of irregular defecation, such as constipation or diarrhea
- •The subject has a history of drug or alcohol abuse, or a positive urine screen for alcohol or drugs of abuse/illegal drugs
- •The subject has had treatment with prescription drugs or complementary and alternative medicines (CAM) within 14 days prior to study drug administration, or over the counter (OTC) medication within past week
- •The subject has/had a symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check in
- •The subject is known positive for human immunodeficiency virus (HIV) antibody
- •The subject has a positive test for hepatitis C antibody, or positive test for hepatitis B antigen (HBsAg)
- •The subject has positive tuberculosis (TB) or Quantiferon Gold test
- •The subject has received an experimental agent within 30 days or five half-lives, whichever is longer, prior to study drug administration
- •The subject has had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission
- •The subject has had exposure to significant radiation (eg, serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months prior to check-in
- •The subject has participated in a radio-labeled-study within the last 6 months, participated in more than one other radio-labeled study within the past 12 months
研究组 & 干预措施
ASP015K
Experimental
干预措施: ASP015K (Drug)
结局指标
主要结局
Pharmacokinetic assessment through radiographic and high performance liquid chromatography (HPLC) analysis of blood, urine and feces samples
时间窗: Up to 10 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic MelanomaMalignant MelanomaNCT01164891Hoffmann-La Roche7
进行中（未招募）
1 期
Single Dose Study To Study The Absorption, Metabolism And Excretion Of FamitinibHealthy SubjectsNCT05473468Jiangsu HengRui Medicine Co., Ltd.6
已完成
1 期
A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the BodyAdvanced Solid TumorsPharmacokinetics of 14C-OSI-906NCT01529684Astellas Pharma Global Development, Inc.5
已完成
1 期
A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803HealthyNCT05286281Pfizer6
已完成
1 期
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced CancerAdvanced CancerNCT01583777Acrotech Biopharma Inc.6